Role of Immunotherapy in Gastroesophageal Cancer with Liver Metastasis.

IF 3.4 Q2 ONCOLOGY JNCI Cancer Spectrum Pub Date : 2024-10-22 DOI:10.1093/jncics/pkae105

Sawyer Bawek, Mrinalini Ramesh, Sayuri Gurusinghe, Ali Aijaz, Kristopher Attwood, Nariman Hossein-Javaheri, Sarbajit Mukherjee

{"title":"Role of Immunotherapy in Gastroesophageal Cancer with Liver Metastasis.","authors":"Sawyer Bawek, Mrinalini Ramesh, Sayuri Gurusinghe, Ali Aijaz, Kristopher Attwood, Nariman Hossein-Javaheri, Sarbajit Mukherjee","doi":"10.1093/jncics/pkae105","DOIUrl":null,"url":null,"abstract":"<p><p>The role of immune checkpoint inhibitors (ICIs) for patients with gastroesophageal (GE) cancer with liver metastasis remains unclear. Our objective was to investigate if ICIs are beneficial in patients with GE cancer with liver metastasis. We searched PubMed, Embase, ESMO, and ASCO Meeting Abstracts for phase III randomized clinical trials (RCTs) testing ICIs in metastatic/advanced GE cancer from 2017 to 2023. Seven studies were included. OS was similar among all patients (HR 0.72 [0.67,0.77], p < .001), in patients without (HR 0.73 [0.67,0.81], p < .001, I2 = 0.0%), and with liver metastasis (HR 0.74 [0.67,0.81], p < .001, I2 = 0.0%). PFS was also similar among all patients (HR 0.63 [0.57,0.70], p < .001), without (HR 0.62 [0.51,0.76], p < .001), and with liver metastasis (HR 0.66 [0.57,0.76], p < .001). ICIs showed no difference in benefit in patients with GE cancer regardless of liver metastasis. Future studies could focus on deciphering the tumor microenvironment of liver metastasis as an area of translational research.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Cancer Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncics/pkae105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The role of immune checkpoint inhibitors (ICIs) for patients with gastroesophageal (GE) cancer with liver metastasis remains unclear. Our objective was to investigate if ICIs are beneficial in patients with GE cancer with liver metastasis. We searched PubMed, Embase, ESMO, and ASCO Meeting Abstracts for phase III randomized clinical trials (RCTs) testing ICIs in metastatic/advanced GE cancer from 2017 to 2023. Seven studies were included. OS was similar among all patients (HR 0.72 [0.67,0.77], p < .001), in patients without (HR 0.73 [0.67,0.81], p < .001, I2 = 0.0%), and with liver metastasis (HR 0.74 [0.67,0.81], p < .001, I2 = 0.0%). PFS was also similar among all patients (HR 0.63 [0.57,0.70], p < .001), without (HR 0.62 [0.51,0.76], p < .001), and with liver metastasis (HR 0.66 [0.57,0.76], p < .001). ICIs showed no difference in benefit in patients with GE cancer regardless of liver metastasis. Future studies could focus on deciphering the tumor microenvironment of liver metastasis as an area of translational research.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

免疫疗法在胃食管癌肝转移中的作用

免疫检查点抑制剂（ICIs）对胃食管癌肝转移患者的作用仍不明确。我们的目的是研究 ICIs 是否对胃食管癌肝转移患者有益。我们检索了PubMed、Embase、ESMO和ASCO会议摘要，以寻找2017年至2023年期间测试ICIs治疗转移性/晚期GE癌的III期随机临床试验（RCT）。共纳入七项研究。所有患者的 OS 相似（HR 0.72 [0.67,0.77], p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊